Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 394,654,592
  • Shares Outstanding, K 2,682,900
  • Annual Sales, $ 12,255 M
  • Annual Income, $ -12,121,000 K
  • 36-Month Beta 0.59
  • Price/Sales 5.14
  • Price/Cash Flow 15.32
  • Price/Book 6.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.95
  • Number of Estimates 7
  • High Estimate 1.97
  • Low Estimate 1.93
  • Prior Year 1.74
  • Growth Rate Est. (year over year) +12.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
139.66 +5.86%
on 11/27/18
148.99 -0.77%
on 12/04/18
+3.16 (+2.18%)
since 11/13/18
3-Month
132.23 +11.81%
on 10/12/18
148.99 -0.77%
on 12/04/18
+7.95 (+5.68%)
since 09/13/18
52-Week
118.62 +24.63%
on 05/29/18
148.99 -0.77%
on 12/04/18
+4.95 (+3.46%)
since 12/13/17

Most Recent Stories

More News
J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study

J&J's (JNJ) psoriasis drug Tremfya proves to be better than Novartis' Cosentyx in phase III head-to-head study for treating adult patients with moderate to severe plaque psoriasis.

MRK : 79.01 (+1.28%)
JNJ : 147.84 (+0.50%)
NVS : 88.40 (+0.31%)
BMY : 53.64 (+0.37%)
Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA

Mallinckrodt (MNK) receives complete response letter from the FDA related to its regulatory application seeking approval for abuse-deterrent reformulation of opioid painkiller, Roxicodone.

JNJ : 147.84 (+0.50%)
MRK : 79.01 (+1.28%)
MNK : 20.82 (-0.14%)
BMY : 53.64 (+0.37%)
Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug

Eli Lilly (LLY) signs a deal with AC Immune to jointly develop Morphomer tau aggregation inhibitors, which have the potential to treat Alzheimer's disease (AD) and other neurodegenerative diseases.

ACIU : 11.70 (+5.41%)
JNJ : 147.84 (+0.50%)
MRK : 79.01 (+1.28%)
LLY : 114.86 (+0.45%)
5 Dow Stocks Stand Tall Despite Index's Loss of 2018 Gains

The Dow portfolio has depicted weak trends in 2018, thanks to concerns surrounding trade and interest rates. Nevertheless, strong U.S. economic fundamentals are likely to aid revival.

INTC : 48.29 (+0.96%)
MRK : 79.01 (+1.28%)
JNJ : 147.84 (+0.50%)
AXP : 106.70 (-0.73%)
BA : 325.47 (-0.37%)
Janssen Signs Results-Based Contract with Oklahoma Health Care Authority (OHCA) for its Long-Acting Injectable Schizophrenia Medicines

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today a results-based contract for long-acting injectable schizophrenia medicines (LAIs) with the Oklahoma Health Care Authority (OHCA),...

JNJ : 147.84 (+0.50%)
5 Dow Stocks Defying the Index's YTD Plunge

The Dow 30 has been witnessing volatility in 2018 so far on account of investors' apprehension regarding investing in risky assets like equities.

MSFT : 109.45 (+0.34%)
JNJ : 147.84 (+0.50%)
MRK : 79.01 (+1.28%)
AXP : 106.70 (-0.73%)
BA : 325.47 (-0.37%)
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $147.10, marking a +0.41% move from the previous day.

JNJ : 147.84 (+0.50%)
Watch for Johnson&Johnson to Potentially Pullback After Gaining 1.21% Yesterday

Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $147.00 to a high of $148.48. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

JNJ : 147.84 (+0.50%)
Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya

The CHMP postpones the review timeline of Portola's (PTLA) Ondexxya (in the EU. Shares take a hit.

JNJ : 147.84 (+0.50%)
HKMPF : 24.0000 (-9.08%)
PTLA : 19.11 (-11.40%)
BSTC : 60.00 (-2.49%)
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the ECLIPSE study demonstrating that TREMFYA® (guselkumab) was superior to Cosentyx® (secukinumab)* in treating...

JNJ : 147.84 (+0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 149.53
1st Resistance Point 148.69
Last Price 147.84
1st Support Level 146.90
2nd Support Level 145.95

See More

52-Week High 148.99
Last Price 147.84
Fibonacci 61.8% 137.39
Fibonacci 50% 133.81
Fibonacci 38.2% 130.22
52-Week Low 118.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar